Loading patent…
AssigneeAnthrogenesis Corporation
InventorsRobert J. Hariri, Mohammad A. Heidaran, Lin Kang, Neerav Dilip Padliya, Ajai Pal, Vanessa Voskinarian-Berse, Andrew Zeitlin, Xiaokui Zhang
Estimating the term…
Provided herein are placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells.
A method of suppressing the proliferation of tumor cells comprising contacting the tumor cells with human placental perfusate cells, wherein said placental perfusate cells comprise CD56+ placental intermediate natural killer (PINK) cells.
A method of suppressing the proliferation of tumor cells comprising contacting the tumor cells with a plurality of CD56+, CD16− PINK cells.
A method of suppressing the proliferation of tumor cells comprising contacting the tumor cells with combined natural killer cells, wherein said combined natural killer cells comprise PINK cells isolated from placental perfusate and natural killer cells isolated from umbilical cord blood, and wherein said umbilical cord blood is isolated from the placenta from which said placental perfusate is obtained.
Dependencies are inferred from the claim text.